SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

SUMOylation, a posttranslational modification, regulates proteins by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a lysine (Lys) residue on target proteins. Here we use TAK-981, a selective SUMO-activating enzyme (SAE) inhibitor, to inhibit global SUMOylation in glucocorticoid sensitive and resistant multiple myeloma cell lines. Overall design: Human multiple myeloma cell lines MM1.S (glucocorticoid sensitive) and MM1.R (glucocorticoid resistant) were treated with 0.1µM TAK-981, or 1µM Dexamethasone or combo (0.1µM TAK-981 and 1µM Dexamethasone) for 48 h in duplicate, total RNAs were extracted and sequenced.